Clinical Trials Logo

Filter by:
NCT ID: NCT05181839 Completed - Clinical trials for X-Linked Hypophosphatemia

A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

Start date: November 24, 2021
Phase:
Study type: Observational [Patient Registry]

An observational, prospective, mixed-methods study involving the integration of quantitative and qualitative data exploring the lived experience of burosumab-treated adolescents with XLH at the end of skeletal growth.

NCT ID: NCT05180955 Completed - Clinical trials for Pneumothorax and Air Leak

The Role of Clamping Before Removal of a Pneumothorax Drain Connected to a Digital Drainage System.

Start date: September 16, 2022
Phase: N/A
Study type: Interventional

The study will be conducted as a, prospective, open label, non-inferiority, randomized controlled trial. In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data. In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed. Primary outcome measure: recurrent pneumothorax after chest tube removal requiring chest tube reinsertion

NCT ID: NCT05178550 Completed - Healthy Volunteers Clinical Trials

A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.

Start date: December 17, 2021
Phase: Early Phase 1
Study type: Interventional

In this study biomarkers in the blood after exposure to heparin in the fasted state or after a high-fat meal will be investigated. Heparin will be administered as an intravenous (iv) injection (injection directly in a blood vessel). In this study, the effects of administration of heparin will be compared with the effects of administration of normal saline which will also be administered as an iv injection.

NCT ID: NCT05175560 Completed - Healty Babies Clinical Trials

Baby Breathing Monitoring @Home

Start date: February 7, 2022
Phase:
Study type: Observational

To give reassurance to parents, Philips would like to add algorithms to the NightOwl baby monitor to be able to measure baby behavior and physiology. In this study, the investigators aim to investigate the applicability of in-house breathing algorithms, and to develop algorithms, for babies sleeping in a home setting. The data collection will be divided in several sub-studies, either e.g. matching different development steps in the development of the algorithm or focusing on a specific baby population (e.g. specific age range). In general, babies will be monitored (audio, video, activity) for 24 -48 hours under their habitual sleeping conditions. Step 1: 3 full data sets will be recorded of babies in bed aged 3 weeks to about 3-4 months, who are not able to turn over yet. Data will be analyzed and study set-up will be checked. Parents will be asked to keep a baby sleep diary and a questionnaire will be filled in at the start, with questions regarding the sleep behavior of their child. At the end, parents will be asked to fill in a questionnaire with sleep-related and feedback questions. In step 2, 5 full data sets will be collected following the same procedure as step 1. In step 3 12 full data sets will be collected following the same procedure as step 1. After each step, the study setup including the algorithms, will be reviewed based on the obtained data. All modifications to this protocol will be submitted as amendments. After step 1 and 2, the Mother and Child Care Business unit of Philips and other relevant stakeholders will be updated on the progress and findings by means of a (short) meeting and PowerPoint slides. After step 3, a report will be written. The PowerPoint slides shared after Step 1 and 2 will be incorporated in this report.

NCT ID: NCT05169996 Completed - Food Intake Clinical Trials

Virtual Reality Effects on Food Intake Game to Decrease Food Intake

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

Aims: - The first aim was to replicate the pre-exposure effect. This was done by assessing the effect of exposing participants to a puzzle game with real foods compared to real nonfoods on food intake. - The second aim was to investigate the potential of VR for eliciting the pre-exposure effect. This was done by comparing the effect of a VR puzzle game with foods to a VR puzzle game with nonfoods on food intake. - The third aim was to assess the effect of branding in VR on brand responses and the role of emotional responses herein. This was done by comparing a branded virtual puzzle game with foods with a (non-branded) virtual puzzle game with foods. Study design: a randomized 2 (game: real vs virtual) x 2 (product: food vs non-food) between-subjects design lab experiment, the effectiveness of pre-exposure to food in a VR game is tested. A fifth condition was added ("VR x branded food") in order to examine brand effects.

NCT ID: NCT05169684 Completed - Clinical trials for Prostatic Neoplasms, Castration-Resistant

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandrogen therapy and have not received chemotherapy for mCRPC.

NCT ID: NCT05163834 Completed - Healthy Volunteers Clinical Trials

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Start date: November 17, 2021
Phase: Phase 1
Study type: Interventional

This is a randomized, open-label, placebo-controlled phase 1 study in healthy adult volunteers to provide information regarding vaccination with a common pneumococcal polysaccharide vaccine while receiving efgartigimod.

NCT ID: NCT05163691 Completed - Healthy Volunteers Clinical Trials

Pharmacokinetics of GH001 in Healthy Volunteers

Start date: June 21, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to investigate the serum pharmacokinetics of 5-MeO-DMT and its metabolite, bufotenine in healthy volunteers in a double-blind, placebo-controlled, randomized study design with single, inhaled doses of GH001 and in an open-label, non-randomized study design with intra-subject dose-escalation of GH001. As a secondary objective, the safety and tolerability of GH001, the mental health and well-being of the subjects after GH001 dosing(s), the pharmacodynamic profile of GH001 as evaluated by its psychoactive effects, and cognitive measures are also assessed.

NCT ID: NCT05162157 Completed - COPD Asthma Clinical Trials

Home Spirometry in Primary Care: an Implementation Study

Spiro@Home
Start date: September 27, 2021
Phase:
Study type: Observational

Rationale: Spirometry is essential in the diagnosis of airway disease and can be useful in monitoring patients. Despite the essential role, spirometry remains largely underused in primary care. Due to Coronavirus disease (COVID-19), the use of office spirometry is contraindicated in many countries. Furthermore, spirometric devices are costly and personnel requires special training. Referral for spirometry increases the cost for patients and lowers the feasibility. Part of the reason for underdiagnosis of airway disease are the specific situations (such as exercise-induced asthma) in which spirometry in office setting might not reveal abnormalities. In recent years, handheld spirometry linked to phones/apps has been developed for study purposes and remote monitoring. Objective: To study the feasibility, quality and added value of at-home spirometry for the diagnosis and monitoring of asthma and Chronic Obstructive Pulmonary Disease (COPD) in primary care.

NCT ID: NCT05161715 Completed - Clinical trials for Early Alzheimer's Disease

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Start date: January 12, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.